Skip to main content
Equibles
VSEED logo

VSEED · Vsee Health, Inc. · Metrics

Track VSEED — free

Use VSEED with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VSEED.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.88 +0.00 (+0.00%) At close · Oct 19
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has determined that principal conditions including the Company’s liquidity condition and historical operating losses raise substantial doubt about the Company’s ability to continue as a going concern for a period of time of at least one year after the date that the accompanying consolidated financial statements are issued. ... There is no assurance that the Company’s plans to alleviate such concerns will be successful or successful within one year after the date the condensed consolidated financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Customer concentration — top customer 46% of revenue

One customer — 46% of revenue (the three months ended June 30, 2026)

“The Company has one customer whose revenue accounted for approximately 46% and 43% of the Company's total revenue for the three months ended June 30, 2026, and six months ended June 30, 2026, respectively.”

One customer — 43% of revenue (the six months ended June 30, 2026)

“The Company has one customer whose revenue accounted for approximately 46% and 43% of the Company's total revenue for the three months ended June 30, 2026, and six months ended June 30, 2026, respectively.”

2 customers — 23% of receivables (June 30, 2026)

“In aggregate, the Company had two customers whose accounts receivable represented 23% of the Company's total accounts receivable as of June 30, 2026.”

3 customers — 43% of receivables (December 31, 2025)

“In the aggregate, the Company had three customers whose accounts receivable represented 43% of the Company's total accounts receivable as of December 31, 2025.”
View the 10-Q filed Aug 14, 2026
Market Cap
$106.56M
Shares
56.68M
Volume · Oct 19 19K Avg daily vol (3M) 7.02M

VSEED metrics

68 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.88
Market cap
$106.56M

Price action

20 metrics
Price change (1W)
-3.6%
Price change (30D)
+11,650.0%
Price change (3M)
+1,838.1%
Price change (6M)
+649.0%
Price change (YTD)
+402.7%
Price change (1Y)
+262.9%
Trailing year
Price change (5Y)
—
52-week high
$2.28
52-week low
$0.01
Change from 52-week high
-17.5%
Change from 52-week low
+15,566.7%
Annualized volatility
8,938.3%
Annualized volatility (3M)
17,664.6%
Beta
-3.7
RSI (14D)
62.8
Price vs SMA 50
+193.4%
Price vs SMA 200
+461.3%
Avg volume (3M)
7.05M
Relative volume
0.0
Average dollar volume
$510,509

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
56.68M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
7.2×
reciprocal yield 14.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
7.1×
reciprocal yield 14.0%
P / book
14.0
reciprocal yield 7.1%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-12.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.9×
reciprocal yield 116.5%
EV / revenue historical average (5Y)
0.9×
reciprocal yield 116.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
42.0%
Operating margin
-79.3%
Trailing 12 months
Net margin
-100.6%
Gross profit (TTM)
$6.29M
Operating profit (TTM)
−$11.87M
Net income (TTM)
−$13.51M
Trailing 12 months
Diluted EPS (TTM)
$-0.54
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.16

Growth

11 metrics
Revenue growth YoY
+48.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$14.96M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+226.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-178.0%
Return on assets
-80.8%
Debt / equity
0.1
Current ratio
0.4
EBITDA (TTM)
−$9.28M
Free cash flow (TTM)
—
Quick ratio
0.4
Interest coverage
-4.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$662,012
Latest balance sheet
Cash & equivalents
$454,151
Total assets
$16.73M
Total debt
$1.12M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.31M
Capital expenditures (TTM)
$129,928
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
37
13F filer change QoQ
+4
Institutional ownership
17.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
11.7%
Private-fund adviser ownership
8.8%
Active holders' share change QoQ
+54.6%
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
29 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1864531 CUSIP 92919Y201 13F (30d) 1 filings 1 filers Visit website Investor relations